Effectiveness of XBB.1.5 Monovalent COVID‐19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS‐EHR Network Study

• Author(s): Monge, Susana ; Humphreys, James ; Nicolay, Nathalie ; Braeye, Toon ; Van Evercooren, Izaak ; Holm Hansen, Christian ; Emborg, Hanne‐Dorthe ; Sacco, Chiara ; Mateo‐Urdiales, Alberto ; Castilla, Jesús ; Martínez‐Baz, Iván ; de Gier, Brechje ; Hahné, Susan ; Meijerink, Hinta ; Kristoffersen, Anja Bråthen ; Machado, Ausenda ; Soares, Patricia ; Nardone, Anthony ; Bacci, Sabrina ; Kissling, Esther ; Nunes, Baltazar
• Date: 2024
• Persistent ID: http://hdl.handle.net/10400.18/10409
• Origin: Repositório Científico do Instituto Nacional de Saúde
• Subject(s): COVID-19; SARS‐CoV‐2; Cohort Design; Electronic Health Records; Vaccine Effectiveness; Hospitalisation; Multicountry Study; Europe; Infecções Respiratórias; VEBIS-Lot 4; Vacina COVID-19; Efetividade; Registos Eletrónicos em Saúde; Cuidados de Saúde
• Document Type: Journal article
• Language: English
• Contributor(s): Repositório Científico do Instituto Nacional de Saúde

Description

Using a common protocol across seven countries in the European Union/European Economic Area, we estimated XBB.1.5 monovalent vaccine effectiveness (VE) against COVID-19 hospitalisation and death in booster-eligible ≥ 65-year-olds, during October–November 2023. We linked electronic records to construct retrospective cohorts and used Cox models to estimate adjusted hazard ratios and derive VE. VE for COVID-19 hospitalisation and death was, respectively, 67% (95%CI: 58–74) and 67% (95%CI: 42–81) in 65- to 79-year-olds and 66% (95%CI: 57–73) and 72% (95%CI: 51–85) in ≥ 80-year-olds. Results indicate that periodic vaccination of individuals ≥ 65 years has an ongoing benefit and support current vaccination strategies in the EU/EEA.